NRAMP allows for the collection and collation of comprehensive data on maternal, fetal and neonatal development, including outcomes and sequelae both antenatally and postnatally. Maternal interviews, clinical interviews and medical record searching are conducted, in order to develop a complete data set for each mother and baby. The progress of mothers and babies are tracked until babies are 12 months old. NRAMP is current and ongoing; results will be presented on neonatal outcomes, including maternal medications, serious adverse event outcomes, NICU and SCN admissions, infant developmental milestones and levels of functioning at 12 months.
The targeted development of evidence-based clinical guidelines will expand our knowledge, understanding and care plan options for babies of mothers who took antipsychotic medication during pregnancy. This includes fetal/neonatal development and outcomes, treatment options, sequelae and follow up, where necessary and the opportunity to gain an improved understanding of these concerns as we provide for healthy mothers, babies, families and communities, both now and in the future.